132 related articles for article (PubMed ID: 38268156)
1. Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial.
Sun F; Wang HJ; Liu Z; Geng S; Wang HT; Wang X; Li T; Morel L; Wan W; Lu L; Teng X; Ye S
Lancet Rheumatol; 2020 Apr; 2(4):e210-e216. PubMed ID: 38268156
[TBL] [Abstract][Full Text] [Related]
2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
3. Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial.
Sun F; Huang W; Chen J; Zhao L; Zhang D; Wang X; Wan W; Dai SM; Chen S; Li T; Ye S
Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35105722
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
[TBL] [Abstract][Full Text] [Related]
5. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
Furie RA; Morand EF; Bruce IN; Manzi S; Kalunian KC; Vital EM; Lawrence Ford T; Gupta R; Hiepe F; Santiago M; Brohawn PZ; Berglind A; Tummala R;
Lancet Rheumatol; 2019 Dec; 1(4):e208-e219. PubMed ID: 38229377
[TBL] [Abstract][Full Text] [Related]
6. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial.
Park JK; Kim M; Jung JI; Kim JY; Jeong H; Park JW; Winthrop KL; Lee EB
Lancet Rheumatol; 2024 Jun; 6(6):e352-e360. PubMed ID: 38710192
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
[TBL] [Abstract][Full Text] [Related]
9. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604
[TBL] [Abstract][Full Text] [Related]
10. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
11. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial.
Humrich JY; von Spee-Mayer C; Siegert E; Bertolo M; Rose A; Abdirama D; Enghard P; Stuhlmüller B; Sawitzki B; Huscher D; Hiepe F; Alexander T; Feist E; Radbruch A; Burmester GR; Riemekasten G
Lancet Rheumatol; 2019 Sep; 1(1):e44-e54. PubMed ID: 38229359
[TBL] [Abstract][Full Text] [Related]
12. Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials.
Sun F; Geng S; Wang H; Wang H; Liu Z; Wang X; Li T; Wan W; Lu L; Teng X; Morel L; Ye S
Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33093216
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Bruce IN; Nami A; Schwetje E; Pierson ME; Rouse T; Chia YL; Kuruvilla D; Abreu G; Tummala R; Lindholm C
Lancet Rheumatol; 2021 Feb; 3(2):e101-e110. PubMed ID: 38279367
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
Lai ZW; Kelly R; Winans T; Marchena I; Shadakshari A; Yu J; Dawood M; Garcia R; Tily H; Francis L; Faraone SV; Phillips PE; Perl A
Lancet; 2018 Mar; 391(10126):1186-1196. PubMed ID: 29551338
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Morand EF; Vital EM; Petri M; van Vollenhoven R; Wallace DJ; Mosca M; Furie RA; Silk ME; Dickson CL; Meszaros G; Jia B; Crowe B; de la Torre I; Dörner T
Lancet; 2023 Mar; 401(10381):1001-1010. PubMed ID: 36848918
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D
Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
[TBL] [Abstract][Full Text] [Related]
18. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial.
Mathian A; Pha M; Haroche J; Cohen-Aubart F; Hié M; Pineton de Chambrun M; Boutin THD; Miyara M; Gorochov G; Yssel H; Cherin P; Devilliers H; Amoura Z
Ann Rheum Dis; 2020 Mar; 79(3):339-346. PubMed ID: 31852672
[TBL] [Abstract][Full Text] [Related]
19. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
Thanou A; Chakravarty E; James JA; Merrill JT
Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
[TBL] [Abstract][Full Text] [Related]
20. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
Mok CC; Ying SK; Ma KM; Wong CK
Lupus; 2013 Dec; 22(14):1470-8. PubMed ID: 24113197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
